Table 7.

Ongoing (until January 2020) Advanced Hepatocellular Carcinoma trials assessing Nivolumab/Ipilimumab combination.

End Time	Enrollment	Trial Phase	Primary Endpoints	Treatment Arms	Clinical Trial Identifier
2022	32	1/2	Delay to surgery (Time Frame: Up to Day 89) Incidence of treatment-emergent adverse events (Time Frame: Up to Day 127)	Ipilimumab (1 mg/kg, once every 3 weeks, for 3 weeks) + Nivolumab (3 mg/kg, once every 3 weeks, for 6 weeks)	NCT03682276
2023	1084	3	OS (Time Frame: up to 4 years)	Arm A: Nivolumab + Ipilimumab Arm B: Sorafenib/Lenvatinib	NCT04039607
2024	12	1	Drug-related toxicities (Time Frame: 4 years) Fold change in interferon-producing DNAJB1-PRKACA-specific cluster of differentiation 8(CD8) and 4 (CF4) T cells	DNAJB1-PRKACA peptide vaccine, Nivolumab, and Ipilimumab	NCT04248569
2022	1097	1/2	Safety and Tolerability of nivolumab ORR, Safety, and Tolerability of nivolumab plus ipilimumab	Non-infected: Nivolumab HCV-infected: Nivolumab HBV-infected: Nivolumab Nivolumab plus Ipilimumab Combination Nivolumab plus Cabozantinib Combination Nivolumab plus Ipilimumab plus Cabozantinib	NCT01658878
2022	32	1/2		Ipilimumab Nivolumab	NCT03682276